204 related articles for article (PubMed ID: 30005865)
21. MEK inhibition enhances oncolytic virus immunotherapy through increased tumor cell killing and T cell activation.
Bommareddy PK; Aspromonte S; Zloza A; Rabkin SD; Kaufman HL
Sci Transl Med; 2018 Dec; 10(471):. PubMed ID: 30541787
[TBL] [Abstract][Full Text] [Related]
22. Fusogenic oncolytic herpes simplex viruses as a potent and personalized cancer vaccine.
Li QX; Liu G; Zhang X
Curr Pharm Biotechnol; 2012 Jul; 13(9):1773-85. PubMed ID: 21740353
[TBL] [Abstract][Full Text] [Related]
23. [The Advances of Oncolytic Herpes Simplex Virus in Cancer Therapy].
Hao M; Huang C; Xia N
Bing Du Xue Bao; 2016 Jul; 32(4):516-22. PubMed ID: 29996042
[TBL] [Abstract][Full Text] [Related]
24. Syncytial Mutations Do Not Impair the Specificity of Entry and Spread of a Glycoprotein D Receptor-Retargeted Herpes Simplex Virus.
Okubo Y; Uchida H; Wakata A; Suzuki T; Shibata T; Ikeda H; Yamaguchi M; Cohen JB; Glorioso JC; Tagaya M; Hamada H; Tahara H
J Virol; 2016 Dec; 90(24):11096-11105. PubMed ID: 27707922
[TBL] [Abstract][Full Text] [Related]
25. Folate-conjugated herpes simplex virus for retargeting to tumor cells.
Ye ZQ; Zou CL; Chen HB; Lv QY; Wu RQ; Gu DN
J Gene Med; 2020 Jul; 22(7):e3177. PubMed ID: 32096291
[TBL] [Abstract][Full Text] [Related]
26. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy.
Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V
Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211
[TBL] [Abstract][Full Text] [Related]
27. Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against T-cell immunoglobulin and ITIM domain (TIGIT).
Zuo S; Wei M; He B; Chen A; Wang S; Kong L; Zhang Y; Meng G; Xu T; Wu J; Yang F; Zhang H; Wang S; Guo C; Wu J; Dong J; Wei J
EBioMedicine; 2021 Feb; 64():103240. PubMed ID: 33581644
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.
Roy DG; Geoffroy K; Marguerie M; Khan ST; Martin NT; Kmiecik J; Bobbala D; Aitken AS; de Souza CT; Stephenson KB; Lichty BD; Auer RC; Stojdl DF; Bell JC; Bourgeois-Daigneault MC
Nat Commun; 2021 May; 12(1):2626. PubMed ID: 33976179
[TBL] [Abstract][Full Text] [Related]
29. Oncolytic virus immunotherapy for melanoma.
Dharmadhikari N; Mehnert JM; Kaufman HL
Curr Treat Options Oncol; 2015 Mar; 16(3):326. PubMed ID: 25777572
[TBL] [Abstract][Full Text] [Related]
30. Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma.
Cavalcante L; Chowdhary A; Sosman JA; Chandra S
Am J Clin Dermatol; 2018 Oct; 19(5):657-670. PubMed ID: 29961183
[TBL] [Abstract][Full Text] [Related]
31. Combining oncolytic HSV-1 with immunogenic cell death-inducing drug mitoxantrone breaks cancer immune tolerance and improves therapeutic efficacy.
Workenhe ST; Pol JG; Lichty BD; Cummings DT; Mossman KL
Cancer Immunol Res; 2013 Nov; 1(5):309-19. PubMed ID: 24777969
[TBL] [Abstract][Full Text] [Related]
32. A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines.
Feola S; Chiaro J; Martins B; Russo S; Fusciello M; Ylösmäki E; Bonini C; Ruggiero E; Hamdan F; Feodoroff M; Antignani G; Viitala T; Pesonen S; Grönholm M; Branca RMM; Lehtiö J; Cerullo V
Elife; 2022 Mar; 11():. PubMed ID: 35314027
[TBL] [Abstract][Full Text] [Related]
33. Development of an oncolytic HSV vector fully retargeted specifically to cellular EpCAM for virus entry and cell-to-cell spread.
Shibata T; Uchida H; Shiroyama T; Okubo Y; Suzuki T; Ikeda H; Yamaguchi M; Miyagawa Y; Fukuhara T; Cohen JB; Glorioso JC; Watabe T; Hamada H; Tahara H
Gene Ther; 2016 Jun; 23(6):479-88. PubMed ID: 26905369
[TBL] [Abstract][Full Text] [Related]
34. Herpes simplex virus oncolytic vaccine therapy in melanoma.
Sivendran S; Pan M; Kaufman HL; Saenger Y
Expert Opin Biol Ther; 2010 Jul; 10(7):1145-53. PubMed ID: 20515292
[TBL] [Abstract][Full Text] [Related]
35. A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.
Leoni V; Gatta V; Casiraghi C; Nicosia A; Petrovic B; Campadelli-Fiume G
J Virol; 2017 May; 91(10):. PubMed ID: 28250120
[TBL] [Abstract][Full Text] [Related]
36. CD8(+) T-cell Immune Evasion Enables Oncolytic Virus Immunotherapy.
Pourchet A; Fuhrmann SR; Pilones KA; Demaria S; Frey AB; Mulvey M; Mohr I
EBioMedicine; 2016 Mar; 5():59-67. PubMed ID: 27077112
[TBL] [Abstract][Full Text] [Related]
37. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
38. Generation of an Oncolytic Herpes Simplex Virus 1 Expressing Human MelanA.
Boscheinen JB; Thomann S; Knipe DM; DeLuca N; Schuler-Thurner B; Gross S; Dörrie J; Schaft N; Bach C; Rohrhofer A; Werner-Klein M; Schmidt B; Schuster P
Front Immunol; 2019; 10():2. PubMed ID: 30723467
[TBL] [Abstract][Full Text] [Related]
39. Engineering oncolytic vaccinia virus with functional peptides through mild and universal strategy.
Huang LL; Li X; Liu K; Zou B; Xie HY
Anal Bioanal Chem; 2019 Feb; 411(4):925-933. PubMed ID: 30523361
[TBL] [Abstract][Full Text] [Related]
40. Selective Editing of Herpes Simplex Virus 1 Enables Interferon Induction and Viral Replication That Destroy Malignant Cells.
Liu X; He B
J Virol; 2019 Jan; 93(2):. PubMed ID: 30404809
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
